Pfizer Inc. PFE shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the ...

Pfizer's business may be in better shape than investors think.

Everyone is still arguing about Novo Nordisk (NYSE:NVO | NVO Price Prediction), the Danish obesity juggernaut whose GLP-1 ...

Pfizer is rated a Buy with 55%+ upside potential, driven by a robust pipeline and undervalued forward earnings. Read more on ...

CEO Albert Bourla said on “In Good Company” that pandemic-era urgency allowed an eight-month COVID vaccine timeline.

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a ...

The story gets even more troubling when you consider that the payout ratio is well over 100%, sitting at 130% at the end of ...

The healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Pfizer CEO Albert Bourla joins 'Squawk Box' to discuss the company's obesity drug pipeline.